Návrh dohody o sdílení rizik na základě reálných klinických dat: Případová studie imunoterapie v léčbě renálního karcinomu
| Title in English | Proposal for a risk-sharing agreement based on real clinical data: a case study of immunotherapy in the treatment of renal cell carcinoma |
|---|---|
| Authors | |
| Year of publication | 2024 |
| Type | Article in Periodical (without peer review) |
| MU Faculty or unit | |
| Citation | |
| Description | The collection of real-world data is crucial for retrospective evaluation of the efficacy of innovative therapies, especially in oncology. These data allow the creation and re-evaluation of risk-sharing agreements based on clinical outcomes. This research focused on the design of a reimbursement model based on risk-sharing in the treatment of advanced renal cell carcinoma with nivolumab. Retrospective analysis of medical records of 74 patients showed that implementation of risk-sharing agreements (PBRSA) could lead to cost savings and increased access to treatment. Comparison of real-world time-to-progression (PFS) data with the results of a randomized trial revealed the potential for savings of approximately €91,140 while providing treatment to additional patients. The results underline the importance of transparent data for optimizing the financing of cancer treatment. |
| Related projects: |